OmniAb Inc. Common Stock (OABI)
Stock · NASDAQ · Health Care
$4.59as of 10/16/2026
Price chart
Active signals
OABI Signal Track Record
How signals performed across all stocks →What OABI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -1.5% | 45% | September 2, 2026 |
| Bollinger Band Breakout | 24 | -5.9% | 42% | August 7, 2026 |
| Bollinger Band Breakdown | 21 | -1.4% | 48% | June 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +0.3% | 55% | February 24, 2026 |
| Any 20-session window (baseline) | -1.9% | 45% |
Computed by MarketWall from daily closing prices since July 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OABI
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 89
- Website
- www.omniab.com/
Fundamentals
- 1-day range
- $4.59$4.92
- Market cap
- $324.74M
- P/E (trailing)
- —
- P/E (forward)
- -16.38
- EPS (trailing)
- $-0.36
- Dividend yield
- —
- Beta
- 0.60
- Avg. volume
- 1.47M
How OmniAb Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
OmniAb Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- MXCTMaxCyte Inc. Common Stock$1.3▲ 0.00%Market cap $118.91MP/E —$0.643$1.87
- ONMDOneMedNet Corp Class A Common Stock$4.51▼ 5.05%Market cap $37.18MP/E —$4.9$42.2
- BIAFbioAffinity Technologies Inc. Common Stock$3.73▼ 5.81%Market cap $4.12MP/E —$4.56$80.7
- ISPCiSpecimen Inc. Common Stock$0.917▼ 10.97%Market cap $3.35MP/E —$1.02$36.32
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| MXCT MaxCyte Inc. Common Stock | $118.91M | — | $1.3 | ▲ 0.00% | $0.643$1.87 |
| ONMD OneMedNet Corp Class A Common Stock | $37.18M | — | $4.51 | ▼ 5.05% | $4.9$42.2 |
| BIAF bioAffinity Technologies Inc. Common Stock | $4.12M | — | $3.73 | ▼ 5.81% | $4.56$80.7 |
| ISPC iSpecimen Inc. Common Stock | $3.35M | — | $0.917 | ▼ 10.97% | $1.02$36.32 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration GrowthYahoo · 10/7/2026
- Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12Benzinga · 10/7/2026
- StoneX Maintains Buy on OmniAb, Raises Price Target to $6Benzinga · 10/7/2026
- OmniAb, Inc. (OABI) Analyst/Investor Day TranscriptSeekingAlpha · 10/6/2026
- All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to BuyYahoo · 10/6/2026
- OmniAb, Inc. (OABI) Analyst/Investor Day - SlideshowSeekingAlpha · 10/6/2026
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst DayYahoo · 10/6/2026
- OmniAb to Host Investor & Analyst Day on October 6, 2026Yahoo · 9/14/2026
Insider Activity
Insider Actions →- Nwachuku Amechi Ekeke · August 1, 2026 · Grant800.0K
- Steven Love · June 17, 2026 · Grant40.0K
- Steven Love · June 17, 2026 · Grant20.0K
- Steven Love · June 17, 2026 · Option Exercise20.0K
- John L. Higgins · June 17, 2026 · Grant40.0K
- John L. Higgins · June 17, 2026 · Grant20.0K
- John L. Higgins · June 17, 2026 · Option Exercise20.0K
- Steven C. Crouse · April 21, 2026 · Option Exercise13.3K
- Philip J. Gotwals · April 21, 2026 · Option Exercise13.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 54.13M
- Total value held
- $84.33M
- Institutional holders
- 124
- Unknown14.22M
- Unknown8.11M
- Unknown4.16M
- Unknown3.99M
- Unknown2.93M
- Unknown2.55M
- Unknown2.43M
- Unknown2.07M
- Unknown1.75M
- Unknown1.00M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
OmniAb (OABI) Shares Analyst/Investor Day Slideshow
OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.
OmniAb (OABI) Shares Analyst/Investor Day Slideshow. OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.